Impavido approved to treat tropical parasitic disease

(HealthDay)—Impavido (miltefosine) has been approved by the U.S. Food and Drug Administration to treat adults with leishmaniasis, a tropical disease caused by a parasite that's transmitted by the bites of sand flies.

Most Americans who contract the disease do so traveling overseas, the agency said in a news release.

The drug's safety and effectiveness were evaluated in clinical trials involving more than 700 people. Impavido's label will include a boxed warning that the medication could harm a developing fetus and shouldn't be taken by pregnant women.

Common side effects include nausea, vomiting, diarrhea, headache, loss of appetite, dizziness, , itching, fatigue and elevated liver enzymes, the FDA said.

The drug is produced by Paladin Therapeutics, based in Montreal.


Explore further

Vimizim approved for rare childhood disorder

More information: The U.S. Centers for Disease Control and Prevention has more about leishmaniasis

Copyright © 2014 HealthDay. All rights reserved.

Citation: Impavido approved to treat tropical parasitic disease (2014, March 20) retrieved 2 June 2020 from https://medicalxpress.com/news/2014-03-impavido-tropical-parasitic-disease.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments